Moderna (MRNA) Stock Price Prediction: Rally pauses as analysts split between earnings momentum and a still-wide valuation gap

What changed

Moderna (MRNA) is coming off a strong run, but the latest tape shows the stock digesting gains rather than accelerating. The shares are at $247.59, down 2.79% on the day, with a 24-hour range of $243.43 to $259.24 and futures volume of $22.25 million. That places the stock below its 7-day moving average at $255.65 but above the 20-day and 50-day averages at $231.60 and $217.64, respectively.

The fundamental catalyst is still the third-quarter 2026 update. Moderna said revenue grew 29% to $1.3 billion, cash costs fell 10% to $1.0 billion, and the company was profitable in the quarter. It also raised full-year guidance and now expects revenue growth of 15% to 25%, above its prior outlook of up to 10% versus 2025.

Analyst targets frame the debate

The analyst backdrop is not uniform. Piper Sandler raised its target to $305 from $230 and kept an Overweight rating, citing the Q3 sales beat, higher 2026 revenue guidance, $8 billion of cash, and $3.19 billion of long-term debt. Goldman Sachs also lifted its target, to $195 from $137, while keeping a Neutral rating, pointing to the same earnings beat and improved guidance, alongside optimism around the cancer pipeline.

Broader consensus data is more cautious. PriceTargets.com lists a consensus target of $113.75 from 25 analysts, with 4 Sell, 15 Hold, and 6 Buy ratings. StockAnalysis shows a 12-month target of $158.47 from 23 analysts and an average Hold rating. Those figures sit well below the current price, which is a reminder that recent operational progress has not closed the valuation debate.

Technical structure: trend remains constructive, but momentum is cooling

The chart structure still leans positive. Moderna remains above the 20-day and 50-day averages, and the moving-average setup is described as bullish, with the latest move looking like a pullback to the 7-day line rather than a trend break. RSI at 56.27 is neutral, not stretched, while the Stochastic readings at 47.29 and 37.83 point to a market that is neither overheated nor fully reset.

Momentum, however, has flattened. MACD is shown at 12.3061 with the signal line also at 12.3061, leaving a histogram of 0.0000. That is not a clean acceleration signal. In plain terms, the stock is holding up technically, but the immediate push has stalled.

Key levels traders will watch

Immediate support sits at $240.93, with stronger support at $234.28. On the upside, immediate resistance is $256.74 and strong resistance is $265.90. The pivot point is $250.09, so the stock is trading close to the center of the current range rather than at an extreme.

Volatility remains meaningful, with ATR(14) at $17.97. That argues for wider intraday swings and less confidence in tight stop placement.

Derivatives positioning points to a cautious hedge

Binance perpetual futures data is more defensive than bullish. Funding is neutral at 0.0000%, open interest stands at 21,569.25 contracts, and 24-hour open interest is down 23.70%, which indicates position closing or liquidations rather than fresh build-up. Global Binance accounts are 44.2% long and 55.8% short, while top-trader accounts are 44.1% long and 55.9% short. Taker flow is close to balanced, with a 0.9926 buy/sell ratio.

That mix does not confirm a strong directional crowding signal. It does show that the derivatives market is leaning mildly short while spot price action remains firm relative to longer moving averages.

Read-through

The cleanest read on Moderna right now is that fundamentals improved enough to justify the rally, but not enough to remove skepticism. If the stock can reclaim $256.74 and then $265.90, the current pullback looks like consolidation inside a larger uptrend. If it loses $240.93, the market is likely to retest the $234.28 area, where the next support layer becomes important.